TARGET AUDIENCE
This activity is intended for medical oncologists, radiation oncologists and other healthcare providers involved in the treatment of lung cancer.

OVERVIEW OF ACTIVITY
Lung cancer is a devastating disease with broad-reaching effects on public health, as it accounts for approximately 14% of all new cancer cases in the United States and the most cancer-related deaths among both men and women. Historically, therapeutic progress in squamous cell carcinoma (SCC) of the lung has lagged behind the more common non-small cell lung cancer (NSCLC) histologic subtype of adenocarcinoma, and the complex biology underlying this disease has to date precluded the utilization of many targeted treatment options for these patients. However, over the past several years, a number of clinical trials relevant to patients with SCC of the lung have brought forth a host of clinical successes, many of which are already being operationalized in current practice. Even so, many of these achievements continue to challenge the collective understanding of the management of this disease. Several consensus- and evidence-based treatment guidelines are currently available and aim to assist clinicians with making treatment decisions in the face of this dynamic clinical environment. Despite the existence of these tools, many areas of controversy persist.

To bridge the gap between research and patient care, this special iJournal Club audio program features a one-on-one discussion with a leading lung cancer investigator on the management of metastatic SCC of the lung. By providing access to cutting-edge data and expert perspectives, this CME program will assist medical oncologists in the formulation of up-to-date clinical management strategies.

LEARNING OBJECTIVES

• Assess available and emerging clinical research and related FDA approvals supporting the roles of chemotherapy, biologic therapy, immunotherapy or combination approaches in the management of advanced or metastatic SCC of the lung.
• Appraise the incidence of HER2 alterations and the efficacy of afatinib in patients with advanced SCC of the lung harboring these mutations.
• Utilize recent evidence supporting the potential benefit of targeted therapy for patients with SCC NSCLC found to harbor ERBB mutations to guide clinical management for these patients.
• Review recent therapeutic advances related to the use of anti-PD-1/PD-L1 antibodies as monotherapy or in combination with chemotherapy for metastatic SCC of the lung, and discern how these approaches can be optimally employed in the management of this disease.
• Consider how age, performance status and other biologic and disease-related factors affect the selection of therapy for metastatic SCC of the lung.
• Appreciate oncogenic pathways found to mediate the growth of tumors in patients with SCC of the lung in order to counsel appropriate individuals about ongoing research efforts evaluating novel targeted therapies.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
CME credit is no longer available for this issue

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
CME credit is no longer available for this issue

HOW TO USE THESE CME ACTIVITIES
Audio Program: This CME activity consists of an audio component.
CME credit is no longer available for this issue

Video Program: This CME activity consists of a video component.
CME credit is no longer available for this issue

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and his spouse/partner) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Shirish M Gadgeel, MD
Mary Lou Kennedy Research Professor in Thoracic Oncology
Co-Leader of Thoracic Oncology Research Program
Associate Director for Cancer Care at Networking and Affiliated Centers
Professor, Department of Internal Medicine
Division of Hematology/Oncology
University of Michigan
Ann Arbor, Michigan

Advisory Committee: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Genentech, a member of the Roche Group, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Novocure, Takeda Oncology, Xcovery; Contracted Research: Astellas, Blueprint Medicines, Genentech, a member of the Roche Group, Merck, Takeda Oncology; Data and Safety Monitoring Board: AstraZeneca Pharmaceuticals LP; Travel and Honoraria: Merck.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals Inc.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
Adobe Flash Player 27 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Release date: March 2020
Expiration date: March 2021